PHIO
Phio Pharmaceuticals CorpMarquee-fund ownership over time
Current holders
Sorted by tenure (longest first)| Fund | First disclosed | Held | Entry price | Latest close | Return on entry |
|---|---|---|---|---|---|
| Two Sigma Investments | Q1 2026(8Q snapshot) | 1Q | $0.00 | — | — |
“Return on entry” is the price-only move from the fund's first disclosure to today — it ignores any adds, trims, or dividends. A fund that built its position over multiple quarters has a true cost basis somewhere between entry price and latest close; this figure is the upper bound.
Past holders
Funds that exited at some point| Fund | Last entry | Exited | Entry → Exit | Return |
|---|---|---|---|---|
| Citadel Advisors 2× in & out | Q1 2025 | Q2 2025 | — | +0% |
Insider activity
Form 4 — officers, directors, 10%+ ownersFiled within two business days of each transaction by anyone with material insider status at Phio Pharmaceuticals Corp.. Pair with the holders table above as a sanity check: heavy insider buying alongside marquee-fund accumulation is the strongest accumulation signal; heavy insider selling alongside fund exits is the strongest distribution signal.
30d / 90d windows measured from Feb 6, 2026 — the most recent Form 4 on file — not from today.
- Form 40001683168-26-000813Feb 6, 2026
- Form 40001683168-26-000811Feb 6, 2026
- Form 40001683168-26-000809Feb 6, 2026
- Form 40001683168-26-000807Feb 6, 2026
- Form 40001683168-26-000805Feb 6, 2026
- Form 40001683168-26-000803Feb 6, 2026
- Form 40001683168-26-000013Jan 2, 2026
- Form 40001683168-25-009349Dec 29, 2025
- Form 40001683168-25-008639Nov 24, 2025
- Form 40001683168-25-008537Nov 19, 2025
- Form 4/Aamend0001683168-25-006986Sep 15, 2025
- Form 40001683168-25-006961Sep 15, 2025
- Form 40001683168-25-006959Sep 15, 2025
- Form 40001683168-25-006958Sep 15, 2025
- Form 40001683168-25-006957Sep 15, 2025
Fundamentals
XBRL · Phio Pharmaceuticals CorpAnnual figures sourced directly from Phio Pharmaceuticals Corp's 10-K / 10-Q filings via SEC EDGAR XBRL. Latest fiscal year and the year-over-year change, with up to ten years of history.
Recent SEC filings
10-K · 10-Q · 8-K · 13D/G · proxyThe most recent material filings for Phio Pharmaceuticals Corp. — earnings, material events, ownership disclosures, proxy statements. Form 4 insider activity is shown in the panel above.
- 10-QFORM 10-QMay 7, 2026
- 8-KFORM 8-KMay 7, 2026
- 8-KFORM 8-KApr 8, 2026
- 8-KFORM 8-KMar 30, 2026
- 10-KFORM 10-KMar 5, 2026
- 8-KFORM 8-KMar 5, 2026
- 8-KFORM 8-KFeb 18, 2026
- 8-KFORM 8-KFeb 10, 2026
- 8-KFORM 8-KJan 20, 2026
- 8-KFORM 8-KDec 23, 2025
- 8-KFORM 8-KNov 25, 2025
- S-3REGISTRATION STATEMENTNov 20, 2025
- 10-QFORM 10-QNov 13, 2025
- 8-KFORM 8-KNov 13, 2025
- 8-KFORM 8-KNov 6, 2025
Trade history
Every open→close lifecycle across tracked funds| Fund | Open date | Close date | Open price | Close price / current | Return |
|---|---|---|---|---|---|
| Two Sigma Investments | Q1 2026 | open | $0.00 | — | +0% |
| Citadel Advisors | Q1 2025 | Q2 2025 | $0.00 | — | +0% |
| Citadel Advisors | Q3 2024 | Q4 2024 | $0.00 | — | +0% |
- Covers only the 27 marquee funds tracked here, not the full institutional universe. A “0 holders” reading does not mean unowned.
- Heavy funds (Renaissance Technologies, Citadel Advisors, Soros Fund Management, Two Sigma Investments, D.E. Shaw, AQR Capital Management, Millennium Management, Point72 Asset Management) use 8-quarter snapshots, so their pre-2024 history is missing.
- “Current” reflects each fund's most recent 13F — filings lag the actual trade by up to 45 days; positions shown may have changed since.
- Cost = price at the entry filing date. Re-entered positions show the most recent open lot.
- Options, ADRs, and unmapped CUSIPs are excluded from the follower-backtest pipeline that produces these snapshots, so certain holding types won't appear here.